# Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients

> **NCT02529462** · PHASE3 · COMPLETED · sponsor: **AB Biotics, SA** · enrollment: 521 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **GENETIC:** NEUROPHARMAGEN-Guided Treatment
- **DRUG:** Treatment As Usual

## Key facts

- **NCT ID:** NCT02529462
- **Lead sponsor:** AB Biotics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 521 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02529462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02529462, "Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02529462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*